Stapokibart with checkpoint inhibitors for relapsed lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called stapokibart combined with immune checkpoint inhibitors, which are treatments that help your immune system fight cancer. It is for people with lymphoma that has come back or not responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have lymphoma that came back or did not respond to previous treatment, including immune checkpoint inhibitor therapy.
- You must have at least one measurable tumor (a lymph node larger than 15 mm or another tumor spot larger than 10 mm).
- Your organs (bone marrow, liver, kidneys, and blood clotting) must be working well enough, based on blood tests within 7 days before starting the study drug.
- You must not have certain recent treatments or medical conditions, such as active infections, HIV, syphilis, or other cancers in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of three drugs (Golidocitinib, Pegaspargase, and a PD-1 antibody) as the first treatment for people with a rare type of lymphoma called ENKTL. It aims to see if these drugs together can shrink tumors and improve outcomes.
This trial tests a new combination of two drugs (Stapokibart and Tislelizumab) for people with non-small cell lung cancer that has not responded to initial treatment and has no specific gene mutations. The goal is to see if this combo can help when other options have been exhausted.
This trial tests two drugs, Finotonlimab and Stapokibart, for people with head and neck cancer that has come back or spread to other parts of the body. It may help if you've already tried a PD-1 drug and platinum chemotherapy, but the cancer got worse.
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
This study tests an investigational injection (Stapokibart) for people with moderate to severe primary cutaneous amyloidosis, a condition that causes itchy, thickened skin. It aims to see if the drug can safely reduce symptoms in people who haven't gotten enough relief from standard treatments.
This trial tests if adding a new targeted drug (golidocitinib) to standard chemotherapy plus immunotherapy works better than the standard combo alone for people with advanced or non-nasal NK/T-cell lymphoma that hasn't been treated yet.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.